Home > Browse Reports > Biotechnology > RNA Interference Markets

Report Description

RNA Interference Markets
Publication Date: 01-MAY-08
Pages: 122
Study: TMRRNAI
Format/Price: PDF document / $1,999.00
   


Description:



View Sample PDF


Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this TriMark Publications report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing. The main objectives of this study are to: 1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment; 2) obtain a complete understanding of the individual RNAi-testing platforms-from basic principles to clinical applications; 3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets; 4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts; and 5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.





Table of Contents:

  1. 1. Overview 5
  2. 1.1 Objectives 5
  3. 1.2 Scope 5
  4. 1.3 Methodology 7
  5. 1.4 Executive Summary 8
  6. 2. RNA Interference (RNAi) 11
  7. 2.1 Introduction 11
  8. 2.2 Overview of RNA Interference 11
  9. 2.2.1 Classes of Endogenous Small RNAs: siRNA, rasiRNA and miRNA 12
  10. 2.2.2 Mechanism of RNAi In Vivo 13
  11. 2.3 Glossary 16
  12. 2.4 What Areas of Research Does RNAi Impact? 17
  13. 2.4.1 RNAi Technology in Life Sciences Research, Drug Discovery and Development 18
  14. 2.4.1.1 Clinical Trials Featuring RNAi-based Therapeutics 20
  15. 2.4.2 RNAi Technology in Agriculture 24
  16. 2.4.2.1 Companies Utilizing RNAi Technology for Agriculture 25
  17. 3. Technology Trends in RNAi Space 27
  18. 3.1 Overview 27
  19. 3.2 End-User Segmentation 27
  20. 3.3 Technologies for Inducing RNAi 28
  21. 3.3.1 Methods for Detecting Gene Silencing 29
  22. 3.3.2 Libraries of siRNAs/shRNAs to Knockdown Genes En Masse 30
  23. 3.3.2.1 Publicly Available Large-scale Mammalian RNAi Libraries 31
  24. 3.3.2.2 The RNAi Consortium (TRC) 32
  25. 3.3.2.3 RNAi-related Consortia Based in Europe 34
  26. 3.3.3 Comparison of Strategies for Target Validation 36
  27. 3.3.3.1 Market Shifts in RNAi Space: Where Is It Headed? 36
  28. 3.3.3.2 Intellectual Property and Patent Issues 37
  29. 3.3.3.3 Funding in RNAi Space: Grants, Venture Capital and IPOs 39
  30. 3.3.3.4 Partnerships, Alliances, Mergers and Acquisitions 41
  31. 3.3.4 miRNA-Based RNAi: Leading Edge of RNAi Space 43
  32. 3.3.4.1 Biological Function of miRNAs 43
  33. 3.3.4.2 Role of miRNAs in Disease 44
  34. 4. RNAi Market Analysis 54
  35. 4.1 Overview 54
  36. 4.2 Market Data Collection and Respondent Pool 54
  37. 4.2.1 Respondent Pool Characteristics 55
  38. 4.3 RNAi Technologies/Products in Research Applications 57
  39. 4.4 RNAi Technologies/Products: Market Shares (Quantitative) 57
  40. 4.5 Quantitative Metrics of RNAi Usage: Market Opportunity and Growth 60
  41. 4.5.1 Growth of Various Segments in RNAi Space 62
  42. 4.5.2 Product Formats and Representation in RNAi Marketplace 63
  43. 4.6 RNAi Marketplace: Challenges, Unmet Needs and Drivers 69
  44. 4.6.1 Unmet Needs in RNAi Space 70
  45. 4.6.2 RNAi Market: Qualitative Growth Drivers 72
  46. 5. The RNAi Landscape 73
  47. 5.1 Overview 73
  48. 5.2 Market Segmentation of RNAi and Segment Characteristics 73
  49. 5.3 Quantitative Market Opportunities in RNAi Space 75
  50. 5.3.1 Opportunities in miRNA Space 75
  51. 5.3.2 Opportunities in siRNA/shRNA Space 77
  52. 5.4 RNAi Product Offerings and Associated Business Models 78
  53. 6. Company Profiles 81
  54. 6.1 Alfacell Corporation 82
  55. 6.2 Allele Biotechnology and Pharmaceuticals, Inc. 82
  56. 6.3 Alnylam Pharmaceuticals 82
  57. 6.4 Ambion 84
  58. 6.5 Applied Biosystems Group 84
  59. 6.6 Asuragen, Inc. 85
  60. 6.7 Avalon Pharmaceuticals, Inc. 85
  61. 6.8 B-Bridge International, Inc. 85
  62. 6.9 Bio-Rad Laboratories 86
  63. 6.10 Calando Pharmaceuticals, Inc. 86
  64. 6.11 Cepheid 87
  65. 6.12 Cequent 87
  66. 6.13 Clontech Laboratories, Inc. 87
  67. 6.14 CombiMatrix Corporation 88
  68. 6.15 Cyntellect, Inc. 88
  69. 6.16 CytRx Corp. 88
  70. 6.17 Dharmacon 89
  71. 6.18 Dicerna 90
  72. 6.19 Galenea Corporation 90
  73. 6.20 GeneCopoeia, Inc. 90
  74. 6.21 GeneThera, Inc. 91
  75. 6.22 Genlantis 91
  76. 6.23 GenoSensor 91
  77. 6.24 GRL, Inc. 91
  78. 6.25 IDT 92
  79. 6.26 Imgenex Corporation 92
  80. 6.27 Ingenuity Systems 92
  81. 6.28 Isis Pharmaceuticals, LLC 92
  82. 6.29 Intradigm Corporation 94
  83. 6.30 Invitrogen 94
  84. 6.31 InvivoGen 95
  85. 6.32 LC Sciences 95
  86. 6.33 Lentigen Corporation 95
  87. 6.34 Merck & Co., Inc. 95
  88. 6.35 Mirus Bio Corporation 96
  89. 6.36 Monsanto 96
  90. 6.37 Nastech Pharmaceutical Company, Inc. 96
  91. 6.38 New England BioLabs 97
  92. 6.39 Nucleonics, Inc. 97
  93. 6.40 Open Biosystems, Inc. 97
  94. 6.41 OPKO Health, Inc. 98
  95. 6.42 OriGene 98
  96. 6.43 Panomics, Inc. 99
  97. 6.44 PhaseRx 99
  98. 6.45 Promega Corp. 99
  99. 6.46 Quark Pharmaceuticals, Inc. 99
  100. 6.47 RXi Pharmaceuticals Corporation 100
  101. 6.48 Senetek PLC 100
  102. 6.49 Sigma-Aldrich 100
  103. 6.50 Sirna Therapeutics 101
  104. 6.51 Sirnaomics, Inc. 101
  105. 6.52 SomaGenics, Inc. 102
  106. 6.53 System Biosciences 103
  107. 6.54 Tacere Therapeutics 103
  108. 6.55 Targeted Genetics Corporation 104
  109. 6.56 Third Wave Technologies 104
  110. 6.57 Traversa 104
  111. 6.58 Actigenics SA 105
  112. 6.59 Amaxa 105
  113. 6.60 AstraZeneca PLC 106
  114. 6.61 Cenix Bioscience GmbH 106
  115. 6.62 deVGen N.V. 107
  116. 6.63 DNAVision 107
  117. 6.64 Exiqon 107
  118. 6.65 Genovis 108
  119. 6.66 genOway 108
  120. 6.67 imaGenes GmbH 108
  121. 6.68 MWG Biotech AG 109
  122. 6.69 OZ Biosciences 109
  123. 6.70 Prosensa Holding 109
  124. 6.71 QIAGEN 110
  125. 6.72 RNAx GmbH (Germany) 111
  126. 6.73 Roche 112
  127. 6.74 Rosetta Genomics, Ltd. 113
  128. 6.75 Santaris Pharma A/S 113
  129. 6.76 Silence Therapeutics PLC 114
  130. 6.77 TaconicArtemis GmbH 114
  131. 6.78 TRANSAT 114
  132. 6.79 alphaGEN Co., Ltd. 115
  133. 6.80 Benitec, Ltd. 116
  134. 6.81 Bioneer 116
  135. 6.82 CytoPathfinder, Inc. 116
  136. 6.83 Genesis Research & Development Corp. 117
  137. 6.84 GeneDesign, Inc. 117
  138. 6.85 GNI Pharmaceutical Corporation 117
  139. 6.86 Koken Co., Ltd. 118
  140. 6.87 NanoCarrier Co., Ltd. 118
  141. 6.88 Oncolys Biopharma, Inc. 118
  142. 6.89 RealGene Bio-Technologies, Inc. 118
  143. 6.90 Samchully Pharmaceuticals 118
  144. 6.91 Samyang Corp. 119
  145. 6.92 Shanghai Biochip 119
  146. 6.93 Shanghai GenePharma Co. 119
  147. 6.94 Shanghai Genomics, Inc. 120
  148. 6.95 Transgene Biotek, Ltd. 120
  149. 6.96 Tekmira 121
  150. INDEX OF TABLES
  151. Table 2.1: Advantages/Disadvantages of siRNAs and shRNAs as Inducers of RNAi in Mammalian Cells 18
  152. Table 2.2: Prevalence of siRNA-mediated RNAi in Disease Models, as Reported in Scientific Literature 20
  153. Table 2.3: RNAi-based Therapeutics in Clinical Trials 21
  154. Table 2.4: Suppliers of Enabling Technologies and Tools in RNAi Space 22
  155. Table 2.5: Suppliers of siRNA/shRNA Products (by Product/Service Class) 23
  156. Table 3.1: Currently Utilized Technologies for Inducing RNAi-Mediated Knockdown 29
  157. Table 3.2: Comparison of mRNA Detection Technologies 29
  158. Table 3.3: Characteristics of Various Publicly available Mouse and Human RNAi Libraries 31
  159. Table 3.4: Comparison of Formats for Library-Based Gene Knockdown 33
  160. Table 3.5: Strategies for Target Validation by Pharma/Biotech: RNAi and Others 36
  161. Table 3.6: Seminal Patents in RNAi 39
  162. Table 3.7: Venture Capital Raised by Selected Companies in the RNAi Space 40
  163. Table 3.8: List of Public Biotech Companies in RNAi Space 41
  164. Table 3.9: Disease-Related miRNAs 48
  165. Table 3.10: Publicly Available Computational Programs for Identifying miRNA Sequences/Targets 49
  166. Table 3.11: SWOT Analysis of siRNA Oligonucleotides 52
  167. Table 3.12: Transfection Reagents (Lipid-Mediated Delivery) 52
  168. Table 3.13: shRNA Plasmid Constructs 53
  169. Table 3.14: shRNA Pooled Libraries or Arrayed Collections (Retroviral/Lentiviral Delivery) 53
  170. Table 5.1: RNAi Market Segmentation and Research Settings 73
  171. Table 5.2: Segment 1: Basic Life Science Research Utilizing RNAi Tools and Technologies 73
  172. Table 5.3: Segment 2: RNAi for Drug Discovery and Development 74
  173. Table 5.4: Segment 3: RNAi Research for Development of RNAi Therapeutics 74
  174. Table 5.5: Segment 4: RNAi Fee-for-Service Business 75
  175. Table 5.6: Grants Awarded and Research Spending in miRNA Space, 2005-2008 75
  176. Table 5.7: RNAi Opportunity and Market Size: Quantitative Model, 2006-2009 77
  177. INDEX OF FIGURES
  178. Figure 2.1: The miRNA Processing Pathway 14
  179. Figure 2.2: Growth of Scientific Publications Addressing miRNAs, 2001-2008 15
  180. Figure 2.3: Mechanisms of Small RNA-induced Gene Regulation 16
  181. Figure 2.4: Types of RNAi Compounds 18
  182. Figure 2.5: Breakdown of Scientific Publications Related to RNAi by Geographic Region, 2007-2008 19
  183. Figure 3.1: End-User Segmentation of RNAi Space 27
  184. Figure 3.2: RNAi Patents Filed Globally, by Geographical Origin 39
  185. Figure 3.3: Selected Deals in RNAi Space 42
  186. Figure 4.1: Geographical Breakdown of RNAi End-User Survey Respondents 55
  187. Figure 4.2: Affiliation of RNAi End-User Survey Respondents 55
  188. Figure 4.3: Utilization of RNAi Technologies/Products by Respondent Pool 56
  189. Figure 4.4: RNAi Utilization Period: Breakdown of Respondent Pool 56
  190. Figure 4.5: Research Applications Using RNAi Technologies/Products 57
  191. Figure 4.6: Types of RNAi Technologies Currently Utilized 58
  192. Figure 4.7: RNAi Technologies Most Commonly Utilized Currently by End-Users 58
  193. Figure 4.8: Types of RNAi Technologies: Expected Use in Six to 18 Months 59
  194. Figure 4.9: Evolution of Market Shares of RNAi-Inducing Technologies 60
  195. Figure 4.10: Number of Experiments Involving RNAi Conducted per Week 60
  196. Figure 4.11: Range of Research Dollars Spent Monthly on RNAi Research 61
  197. Figure 4.12: RNAi Experiment Throughput Correlated with Type of RNAi Technology Used 62
  198. Figure 4.13: Current RNAi Market Share by Segments 63
  199. Figure 4.14: Growth/Decline Rate of RNAi Marketplace Segments (Six to 18 Months) 64
  200. Figure 4.15: Product Formats Utilization for RNAi Research (Current and Six to 18 Months) 65
  201. Figure 4.16: Companies Offering Product Formats for Currently Used RNAi Products 67
  202. Figure 4.17: RNAi Product Offerings/Formats Use (Projections-Six to 18 Months) 68
  203. Figure 4.18: Percentage Change of RNAi Product Offerings/Formats (Six to 18 Months) 69
  204. Figure 4.19: Key Challenges Faced by End-Users in RNAi Space 70
  205. Figure 4.20: Unmet Needs in RNAi Space Ranked by Importance to End-Users 71
  206. Figure 5.1: Growth and Evolution of miRNA Space 76
  207. Figure 5.2: Elements of RNAi Value Chain 77
  208. Figure 5.3: Growth and Evolution of RNAi (siRNA/shRNA) Space 78
  209. Figure 5.4: Market Revenues Based on Components of siRNA Experimental Paradigm 80

Registration
Browse Reports
Search TriMark
Reading Room
My Account
View Cart
Home  |  Reports  |  Database Tables  |  Conferences  |  Contact Us  
     © 2008 TriMark Publications, LLC. All rights reserved.